IgD multiple myeloma: report of 1 case and review of literature
10.3760/cma.j.cn115356-20210404-00071
- VernacularTitle:IgD型多发性骨髓瘤1例并文献复习
- Author:
Han XU
1
;
Shumin NIE
;
Junxia HUANG
;
Tianlan LI
;
Yan GAO
;
Chunxia MAO
;
Shanshan LIU
;
Yujie XU
;
Jingjing ZHOU
;
Jingjing XIAO
;
Mengying WANG
;
Fanjun MENG
;
Xianqi FENG
Author Information
1. 青岛大学附属医院血液科，青岛 266000
- Keywords:
Multiple myeloma;
IgD;
Extramedullary infiltration;
Daratumumab
- From:
Journal of Leukemia & Lymphoma
2022;31(2):107-110
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features of IgD multiple myeloma (MM) and the effect and prognosis of daratumumab-based combination therapy.Methods:The clinicopathological data of a IgD MM patient with disease progression and extramedullary infiltration treated with daratumumab in the Affiliated Hospital of Qingdao University in December 2019 were retrospectively analyzed.Results:The 74-year-old woman was diagnosed as IgD MM by bone marrow aspiration and immunofixation electrophoresis. The patient was given VD (bortezomib, dexamethasone), RD (lenalidomide, dexamethasone) and ID (ixazomib, dexamethasone) regimens. In June 2020, the patient developed multiple subcutaneous nodules, and she was assessed as progressive disease with extensive extramedullary infiltration. After treated with daratumumab-PAD (liposomal doxorubicin, bortezomib, dexamethasone) regimen, the patient's subcutaneous nodules were significantly reduced and partially disappeared, and the general condition was significantly improved. But the patient was in a cachexia state and finally died of the irregular treatment and disease progression.Conclusions:IgD MM has a low incidence and a short survival period, and there is no uniform standard treatment. The early application of daratumumab combined with proteasome inhibitors, immunomodulators, cytotoxic drugs and hematopoietic stem cell transplantation may improve the overall survival of patients.
